SBWire

The report reveals that the 2-octyldodecanol segment will dominate more than 35% market share and it will surge at a CAGR of 6.7% by the end of the forecast period (2016 – 2024). The present estimated value of the global guerbet alcohols market is more than US$ 800 Mn and the market will stretch at a CAGR of 5.6% and will touch US$ 1316.7 Mn by the end of 2024.

In a new report titled 'Non-Melanoma Skin Cancer Treatment Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025,' Persistence Market Research analyzes the global non-melanoma skin cancer treatment market over an eight year forecast period 2017 – 2025 and throws light on the various factors impacting revenue growth of the market over the said period. The report highlights the market forecasts for the different segments and presents deeper insights for informed decision making.

Growth of the global hepatitis C treatment market is primarily driven by factors such as increase in the prevalence of hepatitis C infections in the U.S. and Canada and rising per capita healthcare expenditure across the globe. Also government initiatives to control infection and various private NGOs creating awareness about treatment is also fueling the market growth. However, high cost associated with hepatitis C treatment drugs and lack of awareness about hepatitis C infection in the regions of Asia Pacific, Middle East and Africa, and Latin America is expected to impede growth of the global hepatitis C treatment market.

By the end of 2022, the global gene expression analysis market is predicted to surpass US$ 4,500 Mn valuation, reflecting a robust CAGR in terms of revenues. The study throws a light on various factors influence the dynamics of global gene expression analysis market, and offers insightful projections, the highlights of which are mentioned below.

The global scar treatment market is witnessing significant growth due to rising prevalence of skin disease and growing expenditure on personal care. Moreover, technological advancements in scar treatment and increasing appearance consciousness among consumers are also driving the growth of the market.

North America is currently the largest veterinary anti-infectives market and is estimated to represent 30.5% value share of the global market by 2025-end, expanding at CAGR of 3.7%. This growth is primarily attributed to the increase in pet ownership and demand for high-quality meat in the U.S. and Canada. Meanwhile, Latin America will continue to be the second most attractive market during the forecast period. The market in Asia Pacific (APAC) is projected to witness the fastest growth over 2025.

The key players in the global foot and mouth disease vaccines market, as stated in a research report, hold small shares in a highly fragmented competitive landscape. The market is largely taken up by a high volume of regional players, a lot of whom are backed by governments and private investors. This has created an intense competitive landscape in the global foot and mouth disease vaccines market which is likely to remain the case over the coming years. The report puts players such as Inova Biotechnologia, Bayer AG, and Brilliant Bio Pharma Ltd., as the leading entities in the global foot and mouth disease vaccines market for 2014.

Growing prevalence of lethal diseases, such as cardiac arrest and heart failure due to changing lifestyle and eating habits is leading to increasing cardiac surgeries and procedures worldwide. Of late, intra-aortic balloon pump has emerged as a cutting-edge product in cardiac management and care. It is basically a polyethylene balloon mounted on a catheter that assists heart during both its rest phase and work phase.

Prominent participants in the global oxygen therapy devices market are Philips Respironics, Inc., AirSep Corporation, Teleflex Incorporated, MAQUET Holding B.V. & Co. KG, ResMed, CareFusion Corporation, Smiths Medical, Invacare Corporation, Fisher and Paykel Healthcare Limited, and DeVilbiss Healthcare LLC. Savvy companies in the market are focusing on product development to bolster their positions. They are also looking to expand their geographical footprints by targeting the relatively underserved markets in Asia Pacific, which holds out a strong promise on account of its large population base and bettering healthcare infrastructure.

The analytical standards market is a key need in the life sciences sector due to the growing need for testing procedures to ensure the safety of consumers of products such as pharmaceuticals and food and beverages. Food safety has become a major concern in recent years due to the growing risk of food poisoning from packaged and fast food. Globalization of the food and beverage and pharmaceuticals sectors has been beneficial for the global analytical standards market, which is likely to prosper in the coming years. The increased government support and public awareness about environmental contamination and the risks posed by the same to human health has also been beneficial for the global analytical standards market, which is likely to experience growing demand from environmental applications in the coming years.

The global capnography equipment market has been studied by Transparency Market Research (TMR) to hold a probable characterization driven by the existence of prominent players such as Nonin Medical, Inc., Nihon Kohden Corporation, Medtronic, Inc., Masimo Corporation, Dragerwerk AG, and Covidien, plc. On account of the development of capnography equipment navigated by technology, most players operating in the market could be involved in conducting research-related tasks. This has been anticipated to help them manufacture novel offerings to attend to the swiftly-changing needs of end users.

Leading players in the urodynamics equipment and disposables market include Albyn Medical, American Medical Systems, Covidien, LABORIE, C.R. Bard, and Medical Measurement Systems. Several players are exploring lucrative growth avenues in several emerging economies by offering solutions for various healthcare settings, in order to consolidate their presence, notes Transparency Market Research (TMR). The presence of a substantial patient pool in these markets is expected to provide substantial opportunities for these companies. Numerous companies are focusing on developing advanced diagnostic solutions for the management of urological dysfunctions in order to boost their offerings.

According to Transparency Market Research (TMR), the global Alzheimer's drugs market is expected to exhibit a consistent 7.5% CAGR in the 2017-2025 forecast period. The market's revenue was valued at more than US$3.6 bn in 2017 and is expected to rise to US$6.4 bn by 2025.

The global elder care services market over an eight year period. Estimated figures indicate significant growth prospects in the global market, providing good opportunities for business expansion and revenue generation for seasoned market players as well as market entrants.

As per a report by Transparency Market Research, the global ophthalmic drugs market will likely attain a value of US$34.3 bn by 2025 from US$24.4 bn in 2016 by registering a tepid CAGR of 4.0% from 2017 to 2025.

The global market for chlamydia infection diagnostics and therapeutics stood at US$1,195.5 mn in 2016 and is projected to rise at a CAGR of 6.0% from 2017 to 2025 to reach a valuation of US$2,002.2 mn in 2025.

Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.

The global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020.

TMR's report predicts that the international veterinary hematology analyzers market could showcase a 6.7% CAGR between the forecast period of 2016 to 2024. The market stood at US$663.0 mn in 2015 and is projected to reach a valuation of US$1,178.9 mn by the end of the forecast period.

The global market for surgical sutures will exhibit a 3.9% CAGR from 2017 to 2025, rising to a valuation of US$5,080.1 mn by 2025.

The MEA defibrillator is expected to grow at a CAGR of 7.60% between the aforementioned forecast period. The overall valuation of the defibrillator market in the Middle East and Africa is estimated to reach the valuation of US$547.8 mn by the fall of 2020 according to the report.

As per the evaluations of the TMR report, the global constipation treatment market was worth US$12.58 bn in 2016. During the forecast period of 2017 to 2025, the TMR report projects the global constipation treatment market to exhibit a healthy CAGR of 7.1%, estimating it to reach an overall valuation of US$22.93 bn by 2025.

According to this market research report, factors that drive the global ostomy drainage bags market are rapidly growing geriatric population and the rising incidence of ulcerative colitis, IBD, Crohn's disease, bladder cancer, and colorectal cancer. Ostomy draining bags refer to prosthetic medical devices that are used for collecting bodily wastes that get excreted after an Ostomy procedure. In this procedure, wastes are diverted from biological systems such as the bladder, ileum, and the colon into an abdominal stoma that is created manually.

The global market for G-protein coupled receptors is expected to rise at a CAGR of 8.8% from 2014 to 2022. The market was worth US$1.63 bn in 2013 and is expected to rise to a valuation of US$3.53 bn by the end of 2022." In terms of therapeutic areas, the market is anticipated to be led by oncology in the years ahead owing to the rising number of cases of cancer. Region-wise, the market is most probably to be led by North America closely led by Europe due to the rise in the case of obesity in these regions.

Glioblastoma multiforme (GBM) is the most lethal and common brain tumor in adults. The treatment modalities available in the market at present include surgical resection, followed by radiotherapy and chemotherapy. Despite being around in the healthcare industry since the last few years, these modalities have done little to decrease the overall mortality rate in patients. Recurrence of disease, glioma stem cell resistance to conventional modalities, and invasiveness of GBM are a few factors hampering the success rate of available treatment methods.